Effects of caspase-9 and survivin gene polymorphisms in pancreatic cancer risk and tumor characteristics

Pancreas

Volumn 39, Issue 7, 2010, Pages 976-980

  Theodoropoulos, George E ^a   Michalopoulos, Nikolaos V ^a   Panoussopoulos, Sotirios George ^a   Taka, Styliani ^b   Gazouli, Maria ^b  

^a HIPPOKRATION HOSPITAL   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

caspase 9; pancreatic cancer; polymorphisms; surviving

Indexed keywords

CASPASE 9;

ADULT; AGED; ALLELE; ARTICLE; CANCER RISK; CARCINOGENESIS; CASE CONTROL STUDY; CELL CYCLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA POLYMORPHISM; FEMALE; GENE FREQUENCY; GENE OVEREXPRESSION; GENOTYPE; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PANCREAS CANCER; PANCREAS TUMOR; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; STATISTICAL SIGNIFICANCE;

AGED; CASE-CONTROL STUDIES; CASPASE 9; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MICROTUBULE-ASSOCIATED PROTEINS; PANCREATIC NEOPLASMS; POLYMORPHISM, GENETIC;

EID: 77957340058     PISSN: 08853177     EISSN: None     Source Type: Journal    
DOI: 10.1097/MPA.0b013e3181d705d4     Document Type: Article

References (30)

1. Evans DB, Lee JE, Pisters PW, et al. Advances in the diagnosis and treatment of adenocarcinoma of the pancreas. Cancer Treat Res. 1997;90:109-125.
2. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin. 2007;57:43-66.
3. Thompson CB. Apoptosis is the pathogenesis and treatment of disease. Science. 1995;267:1456-1462.
4. Raff M. Cell suicide for beginners. Nature. 1998;396:119-122.
5. Danial NN, Korsmeyer SJ. Cell death: critical control points. Cell. 2004;116:205-219.
6. Hengartner MO. The biochemistry of apoptosis. Nature. 2000;407:770-776.
7. Shivapurkar N, Reddy J, Chaudhary PM, et al. Apoptosis and lung cancer: a review. J Cell Biochem. 2003;88:885-898.
8. Hajra KM, Liu JR. Apoptosome dysfunction in human cancer. Apoptosis. 2004;9:691-704.
9. Nicholson DW, Thornberry NA. Caspases: killer proteases. Trends Biochem Sci. 1997;22:299-306.
10. Spitz MR, Wei Q, Dong Q, et al. Genetic susceptibility to lung cancer: the role of DNA damage and repair. Cancer Epidemiol Biomark Prev. 2003;12:689-698. (Pubitemid 36993157)
11. Kiyohara C, Otsu A, Shirakawa T, et al. Genetic polymorphisms and lung cancer susceptibility: a review. Lung Cancer. 2002;37:241-256. (Pubitemid 35286722)
12. Salvesen GS, Duckett CS. IAP proteins: blocking the road to death's door. Nat Rev Mol Cell Biol. 2002;3:401-410.
13. Schimmer AD. Inhibitor of apoptosis proteins: translating basic knowledge into clinical practice. Cancer Res. 2004;64:7183-7190.
14. Liston P, Fong WG, Korneluk RG. The inhibitors of apoptosis: there is more to life than Bcl2. Oncogene. 2003;22:8568-8580.
15. Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med. 1997;3:917-921.
16. Altieri DC. Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene. 2003;22:8581-8589.
17. Li F, Ambrosini G, Chu EY, et al. Control of apoptosis and mitotic spindle checkpoint by surviving. Nature. 1998;396:580-584.
18. Otaki M, Hatano M, Kobayashi K, et al. Cell cycle-dependent regulation of TIAP/m-survivin expression. Biochim Biophys Acta. 2000;1493:188-194.
19. Li F, Altieri DC. The cancer antiapoptosis mouse survivin gene: characterization of locus and transcriptional requirements of basal and cell cycle-dependent expression. Cancer Res. 1999;59:3143-3151.
20. Xu Y, Fang F, Ludewig G, et al. A mutation found in the promoter region of the human survivin gene is correlated to overexpression of survivin in cancer cells. DNA Cell Biol. 2004;23:419-429. (Pubitemid 38981976)
21. Park JY, Park JM, Jang JS, et al. Caspase 9 promoter polymorphisms and risk of primary lung cancer. Hum Mol Genet. 2006;15:1963-1971.
22. Son JW, Kang HK, Chae MH, et al. Polymorphisms in the caspase-8 gene and the risk of lung cancer. Cancer Genet Cytogenet. 2006;169:121-127.
23. Sun T, Gao Y, Tan W, et al. A six-nucleotide insertion-deletion polymorphism in the CASP8 promoter is associated with susceptibility to multiple cancers. Nat Genet. 2007;39:605-613.
24. Frank B, Hemminki K, Wappenschmidt B, et al. Association of the CASP10 V410I variant with reduced familial breast cancer risk and interaction with the CASP8 D302H variant. Carcinogenesis. 2006;27:606-609.
25. MacPherson G, Healey CS, Teare MD, et al. Association of a common variant of the CASP8 gene with reduced risk of breast cancer. J Natl Cancer Inst. 2004;96:1866-1869.
26. Gangwar R, Mandhani A, Mittal RD. Caspase 9 and caspase 8 gene polymorphisms and susceptibility to bladder cancer in North Indian population. Ann Surg Oncol. 2009;16:2028-2034.
27. Altieri DC. The molecular basis and potential role of survivin in cancer diagnosis and therapy. Trends Mol Med. 2001;7:542-547.
28. Jang JS, Kim KM, Kang KH, et al. Polymorphisms in the survivin gene and the risk of lung cancer. Lung Cancer. 2008;60:31-39.
29. Cheng ZJ, Hu LH, Huang SJ. Correlation of -31G/C polymorphisms of surviving promoter to tumorigenesis of gastric carcinoma. Ai Zheng. 2008;27:258-263.
30. Wang YH, Chiou HY, Lin CT, et al. Association between survivin gene promoter-31 C/G polymorphism and urothelial carcinoma risk in Taiwanese population. Urology. 2009;73:670-674.